Medical Device News Magazine

Cardiovascular Associates of America Merges with Novocardia and Announces Strongest Cardiovascular Network in America

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Cardiovascular Associates of America (“CVAUSA”), a comprehensive cardiology practice management services organization, and Novocardia announced that Novocardia has merged with CVAUSA. Novocardia will be the newest division under CVAUSA, focusing on the development, testing, and scalability of innovative care models and new value-based and risk-based contracting models that improve quality care and efficiency while lowering costs. The Florida-based cardiology groups currently partnering with Novocardia, First Coast Heart and Vascular Center in the Jacksonville area and My Cardiologist in the Miami area, will immediately become partner groups within the CVAUSA network.

Tim Attebery will remain chief executive officer of CVAUSA, and Dan Blumenthal, MD, previously chief executive officer of Novocardia, will become president of CVAUSA’s Novocardia division. In the first merger of its kind in the cardiovascular platform space – Novocardia’s founding investor, Deerfield Management, will appoint a representative to the Board and remain a co-investor, while CVAUSA’s investor, Webster Equity Partners, will continue to lead investment strategy for the organization. This merger positions CVAUSA as the preferred value-based cardiovascular network for payers, risk-bearing providers, and self-insured employers.

“This is a very exciting time for CVAUSA and our growth. There is no other network like this in the United States bringing the depth of knowledge, scope of services, high-level care, and treatment to cardiovascular patients,” said Tim Attebery, CEO, CVAUSA. “Teaming up with Dan and leveraging the foundational elements he built at Novocardia,   will allow CVAUSA to expand our footprint rapidly and implement new and better approaches for serving the clinical needs of our patients while also reducing the total cost of cardiovascular care and reducing the financial burden to patients and payers.”

Under Dan’s leadership, Novocardia (meaning a new way to manage cardiovascular patients) will work in partnership with CVAUSA’s Medical Leadership Board to further develop, test, curate, operationalize, and scale proven new care and contracting models across the CVAUSA network which improve the efficiency, quality, access, and cost of cardiovascular care. The Novocardia division will be responsible for continuing to develop and implement new ways cardiovascular disease will be managed, and new methods for reimbursement in a value-based and risk-based environment that reward physicians for shifting care to the lowest cost setting and reducing emergency room visits and hospitalizations.

“Novocardia is thrilled to join the CVAUSA team!” said Dan Blumenthal, president, CVAUSA’s Novocardia division. “In Tim and CVAUSA, we have found a partner which shares our commitment to supporting cardiovascular specialists to continue to drive better outcomes for our patients, improve the value of cardiovascular care, and lead the way towards value-based reimbursement. It is an honor to bring our expertise to CVAUSA and be able to help people throughout the US.”

This significant merger will result in the following:

  • Presence in eight states
  • Eleven partner groups operating across 100+ locations
  • 200+ cardiovascular partner physicians serving 400,000+ active patients

“It’s been a privilege for Deerfield to partner with Dan and his excellent team to build Novocardia and help drive cardiovascular care towards value,” said Stephen Anastos, principal, Deerfield Management.  “We couldn’t imagine better partners than the CVAUSA and Webster teams and are thrilled to have the opportunity to work with them to help build the nation’s leading value-based cardiology network.”

Cardiovascular Associates of America has created a business model that enables cardiovascular specialists to retain physician autonomy and ownership augmented by sharing best practices, access to capital, and executive management support. Cardiology group practices within our network will continue to drive all clinical decisions, manage local operations, and be highly involved in strategic operations at the national level.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”